Lead Product(s) : Edaravone,Dexborneol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Simcere’s Sanbexin® Approved in China for Acute Ischemic Stroke
Details : Sanbexin (a combination of edaravone and dexborneol) is a small molecule, sublingual tablet, which is being evaluated for the treatment of acute ischemic stroke.
Product Name : Sanbexin
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 04, 2024
Lead Product(s) : Edaravone,Dexborneol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Edaravone,Dexborneol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sanbexin Sublingual Tablets Receive Breakthrough Therapy Designation from FDA
Details : Sanbexin (a combination of edaravone and dexborneol) is a small molecule, sublingual tablet, which is being evaluated for the treatment of acute ischemic stroke.
Product Name : Sanbexin
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 09, 2024
Lead Product(s) : Edaravone,Dexborneol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Edaravone,Dexborneol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : NeuroDerm
Deal Size : Inapplicable
Deal Type : Inapplicable
Findings of a Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in JAMA
Details : Sanbexin (a combination of edaravone and dexborneol) is a small molecule, sublingual tablet, which is being evaluated for the treatment of acute ischemic stroke.
Product Name : Sanbexin
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 20, 2024
Lead Product(s) : Edaravone,Dexborneol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : NeuroDerm
Deal Size : Inapplicable
Deal Type : Inapplicable